Skip to main content
Erschienen in: Clinical Research in Cardiology 11/2019

05.04.2019 | Original Paper

Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative

verfasst von: Susan Stienen, João Pedro Ferreira, Nicolas Girerd, Kévin Duarte, Zohra Lamiral, John J. V. McMurray, Bertram Pitt, Kenneth Dickstein, Faiez Zannad, Patrick Rossignol, For the High-Risk Myocardial Infarction Database Initiative

Erschienen in: Clinical Research in Cardiology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

In patients with acute myocardial infarction (MI), BMI < 18.5 kg/m2 and a decrease in BMI during follow-up have been associated with poor prognosis. For BMI ≥ 25 kg/m2, an “obesity paradox” has been suggested. Recently, high visit-to-visit BMI variability has also been associated with poor prognosis in patients with coronary artery disease.

Aims

To simultaneously evaluate several BMI measurements and study their association with cardiovascular (CV) outcomes in a large cohort of patients with acute myocardial infarction (MI) and left ventricular (LV) systolic dysfunction, heart failure (HF) or both.

Methods

The high-risk MI dataset is pooled from four trials: CAPRICORN, EPHESUS, OPTIMAAL and VALIANT. Mean BMI, change from baseline, and variability were assessed during follow-up. The primary outcome was CV death. Cox-proportional hazard models were performed to study the association between the various BMI parameters and outcomes (median follow-up = 1.8 years).

Results

A total of 12,719 patients were included (72% male, mean age 65 ± 11 years). Mean, change and visit-to-visit variability in BMI had a non-linear association with CV death (P < 0.001). Mean BMI < 26 kg/m2 (vs. ≥ 26–35 kg/m2) and BMI decrease during follow-up were independently associated with CV death (adjusted HR 1.32, 95% CI 1.16–1.51, P < 0.001 and adjusted HR 1.57, 95% CI 1.40–1.76, P < 0.001, respectively). Low and high BMI variability (< 2% and > 4%) were associated with increased event-rates, but lost statistical significance in sensitivity analysis including patients with ≥ 5 measurements or excluding patients with HF hospitalization, suggesting that BMI variability may be particularly associated with HF hospitalizations.

Conclusion

Mean BMI < 26 kg/m2 and a BMI decrease during follow-up were independently associated with CV death in patients with MI and LV systolic dysfunction, HF or both. These associations likely reflect poorer patient status and causality cannot be inferred.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Abdulla J, Kober L, Abildstrom SZ, Christensen E, James WP, Torp-Pedersen C (2008) Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries. Eur Heart J 29:594–601PubMed Abdulla J, Kober L, Abildstrom SZ, Christensen E, James WP, Torp-Pedersen C (2008) Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: a pooled analysis of five registries. Eur Heart J 29:594–601PubMed
2.
Zurück zum Zitat Bucholz EM, Krumholz HA, Krumholz HM, Underweight (2016) Markers of cachexia, and mortality in acute myocardial infarction: a prospective cohort study of elderly medicare beneficiaries. PLoS Med 13:e1001998PubMedPubMedCentral Bucholz EM, Krumholz HA, Krumholz HM, Underweight (2016) Markers of cachexia, and mortality in acute myocardial infarction: a prospective cohort study of elderly medicare beneficiaries. PLoS Med 13:e1001998PubMedPubMedCentral
3.
Zurück zum Zitat Gregory AB, Lester KK, Gregory DM, Twells LK, Midodzi WK, Pearce NJ (2017) The relationship between body mass index and the severity of coronary artery disease in patients referred for coronary angiography. Cardiol Res Pract 2017:5481671PubMedPubMedCentral Gregory AB, Lester KK, Gregory DM, Twells LK, Midodzi WK, Pearce NJ (2017) The relationship between body mass index and the severity of coronary artery disease in patients referred for coronary angiography. Cardiol Res Pract 2017:5481671PubMedPubMedCentral
4.
Zurück zum Zitat Herrmann J, Gersh BJ, Goldfinger JZ, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener SJ, Parise H, Fahy M, McAndrew TC, Stone GW, Mehran R (2014) Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol 114:9–16PubMed Herrmann J, Gersh BJ, Goldfinger JZ, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Brener SJ, Parise H, Fahy M, McAndrew TC, Stone GW, Mehran R (2014) Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol 114:9–16PubMed
5.
Zurück zum Zitat Bucholz EM, Beckman AL, Krumholz HA, Krumholz HM (2016) Excess weight and life expectancy after acute myocardial infarction: the obesity paradox reexamined. Am Heart J 172:173–181PubMed Bucholz EM, Beckman AL, Krumholz HA, Krumholz HM (2016) Excess weight and life expectancy after acute myocardial infarction: the obesity paradox reexamined. Am Heart J 172:173–181PubMed
6.
Zurück zum Zitat Niedziela J, Hudzik B, Niedziela N, Gasior M, Gierlotka M, Wasilewski J, Myrda K, Lekston A, Polonski L, Rozentryt P (2014) The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol 29:801–812PubMedPubMedCentral Niedziela J, Hudzik B, Niedziela N, Gasior M, Gierlotka M, Wasilewski J, Myrda K, Lekston A, Polonski L, Rozentryt P (2014) The obesity paradox in acute coronary syndrome: a meta-analysis. Eur J Epidemiol 29:801–812PubMedPubMedCentral
7.
Zurück zum Zitat O’Brien EC, Fosbol EL, Peng SA, Alexander KP, Roe MT, Peterson ED (2014) Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. Circ Cardiovasc Qual Outcomes 7:102–109PubMed O’Brien EC, Fosbol EL, Peng SA, Alexander KP, Roe MT, Peterson ED (2014) Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. Circ Cardiovasc Qual Outcomes 7:102–109PubMed
8.
Zurück zum Zitat Wienbergen H, Gitt AK, Juenger C, Schiele R, Heer T, Towae F, Gohlke H, Senges J, Group MPs (2008) Impact of the body mass index on occurrence and outcome of acute ST-elevation myocardial infarction. Clin Res Cardiol 97:83–88PubMed Wienbergen H, Gitt AK, Juenger C, Schiele R, Heer T, Towae F, Gohlke H, Senges J, Group MPs (2008) Impact of the body mass index on occurrence and outcome of acute ST-elevation myocardial infarction. Clin Res Cardiol 97:83–88PubMed
9.
Zurück zum Zitat Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M, Committee ASA, Investigators (2007) An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 153:74–81PubMed Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M, Committee ASA, Investigators (2007) An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 153:74–81PubMed
10.
Zurück zum Zitat Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA (2008) Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 156:13–22PubMed Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA (2008) Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 156:13–22PubMed
11.
Zurück zum Zitat Chau K, Girerd N, Magnusson M, Lamiral Z, Bozec E, Merckle L, Leosdottir M, Bachus E, Frikha Z, Ferreira JP, Despres JP, Rossignol P, Boivin JM, Zannad F (2018) Obesity and metabolic features associated with long-term developing diastolic dysfunction in an initially healthy population-based cohort. Clin Res Cardiol 107(10):887–896PubMed Chau K, Girerd N, Magnusson M, Lamiral Z, Bozec E, Merckle L, Leosdottir M, Bachus E, Frikha Z, Ferreira JP, Despres JP, Rossignol P, Boivin JM, Zannad F (2018) Obesity and metabolic features associated with long-term developing diastolic dysfunction in an initially healthy population-based cohort. Clin Res Cardiol 107(10):887–896PubMed
12.
Zurück zum Zitat Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71–82PubMedPubMedCentral Flegal KM, Kit BK, Orpana H, Graubard BI (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71–82PubMedPubMedCentral
13.
Zurück zum Zitat Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY, Latini R, Masson S, Agabiti N, Sever P, Delles C, Sattar N, Butler J, Cleland JGF, Kuznetsova T, Staessen JA, Zannad F, Heart OiAi (2017) Risk for incident heart failure: a subject-level meta-analysis from the Heart “OMics” in AGEing (HOMAGE) Study. J Am Heart Assoc 6(5):e005231. https://doi.org/10.1161/JAHA.116.005231 CrossRefPubMedPubMedCentral Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY, Latini R, Masson S, Agabiti N, Sever P, Delles C, Sattar N, Butler J, Cleland JGF, Kuznetsova T, Staessen JA, Zannad F, Heart OiAi (2017) Risk for incident heart failure: a subject-level meta-analysis from the Heart “OMics” in AGEing (HOMAGE) Study. J Am Heart Assoc 6(5):e005231. https://​doi.​org/​10.​1161/​JAHA.​116.​005231 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kennedy LM, Dickstein K, Anker SD, James M, Cook TJ, Kristianson K, Willenheimer R (2006) Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease. Eur Heart J 27:2755–2762PubMed Kennedy LM, Dickstein K, Anker SD, James M, Cook TJ, Kristianson K, Willenheimer R (2006) Weight-change as a prognostic marker in 12 550 patients following acute myocardial infarction or with stable coronary artery disease. Eur Heart J 27:2755–2762PubMed
15.
Zurück zum Zitat Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Thomas RJ, Squires RW, Allison TG (2008) Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 15:336–340PubMed Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Thomas RJ, Squires RW, Allison TG (2008) Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 15:336–340PubMed
16.
Zurück zum Zitat Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376:1332–1340PubMed Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376:1332–1340PubMed
17.
Zurück zum Zitat Dickstein K, Bebchuk J, Wittes J (2012) The high-risk myocardial infarction database initiative. Prog Cardiovasc Dis 54:362–366PubMed Dickstein K, Bebchuk J, Wittes J (2012) The high-risk myocardial infarction database initiative. Prog Cardiovasc Dis 54:362–366PubMed
18.
Zurück zum Zitat Dargie HJ (2000) Design and methodology of the CAPRICORN trial—a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2:325–332PubMed Dargie HJ (2000) Design and methodology of the CAPRICORN trial—a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2:325–332PubMed
19.
Zurück zum Zitat Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390PubMed Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357:1385–1390PubMed
20.
Zurück zum Zitat Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure E and Survival Study I (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMed Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure E and Survival Study I (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321PubMed
21.
Zurück zum Zitat Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15:79–87PubMed Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15:79–87PubMed
22.
Zurück zum Zitat Dickstein K, Kjekshus J (1999) Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 83:477–481PubMed Dickstein K, Kjekshus J (1999) Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 83:477–481PubMed
23.
Zurück zum Zitat Dickstein K, Kjekshus J, Group OSCotOS (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752–760PubMed Dickstein K, Kjekshus J, Group OSCotOS (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752–760PubMed
24.
Zurück zum Zitat Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R (2000) Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 140:727–750PubMed Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R (2000) Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 140:727–750PubMed
25.
Zurück zum Zitat Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial I (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906PubMed Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial I (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906PubMed
26.
Zurück zum Zitat Coiro S, Girerd N, Rossignol P, Bauersachs J, Pitt B, Fay R, Ambrosio G, Solomon SD, Dickstein K, Zannad F (2017) Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clin Res Cardiol 106:722–733PubMed Coiro S, Girerd N, Rossignol P, Bauersachs J, Pitt B, Fay R, Ambrosio G, Solomon SD, Dickstein K, Zannad F (2017) Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clin Res Cardiol 106:722–733PubMed
27.
Zurück zum Zitat von Lueder TG, Girerd N, Atar D, Agewall S, Lamiral Z, Kanbay M, Pitt B, Dickstein K, Zannad F, Rossignol P, High-Risk Myocardial Infarction Database Initiative I (2015) Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 17:1144–1151 von Lueder TG, Girerd N, Atar D, Agewall S, Lamiral Z, Kanbay M, Pitt B, Dickstein K, Zannad F, Rossignol P, High-Risk Myocardial Infarction Database Initiative I (2015) Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 17:1144–1151
28.
Zurück zum Zitat Abdin A, Poss J, Fuernau G, Ouarrak T, Desch S, Eitel I, de Waha S, Zeymer U, Bohm M, Thiele H (2018) Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial. Clin Res Cardiol 107:517–523PubMed Abdin A, Poss J, Fuernau G, Ouarrak T, Desch S, Eitel I, de Waha S, Zeymer U, Bohm M, Thiele H (2018) Revision: prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial. Clin Res Cardiol 107:517–523PubMed
29.
Zurück zum Zitat de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R (2005) TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 26:865–872PubMed de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R (2005) TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 26:865–872PubMed
30.
Zurück zum Zitat Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Kober L, McMurray JJV, Paradigm HF, Investigators A and Committees (2017) Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 70:2490–2500PubMed Mogensen UM, Jhund PS, Abraham WT, Desai AS, Dickstein K, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Kober L, McMurray JJV, Paradigm HF, Investigators A and Committees (2017) Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 70:2490–2500PubMed
31.
Zurück zum Zitat Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart F (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34:1404–1413PubMed Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart F (2013) Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34:1404–1413PubMed
32.
Zurück zum Zitat Zhang J, Begley A, Jackson R, Harrison M, Pellicori P, Clark AL, Cleland JGF (2019) Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis. Clin Res Cardiol 108(2):119–132PubMed Zhang J, Begley A, Jackson R, Harrison M, Pellicori P, Clark AL, Cleland JGF (2019) Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis. Clin Res Cardiol 108(2):119–132PubMed
33.
Zurück zum Zitat Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R, Gissi HF, Val-He FTI (2015) Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail 17:424–433PubMed Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R, Gissi HF, Val-He FTI (2015) Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail 17:424–433PubMed
34.
Zurück zum Zitat Zamora E, Diez-Lopez C, Lupon J, de Antonio M, Domingo M, Santesmases J, Troya MI, Diez-Quevedo C, Altimir S, Bayes-Genis A (2016) Weight loss in obese patients with heart failure. J Am Heart Assoc 5:e002468PubMedPubMedCentral Zamora E, Diez-Lopez C, Lupon J, de Antonio M, Domingo M, Santesmases J, Troya MI, Diez-Quevedo C, Altimir S, Bayes-Genis A (2016) Weight loss in obese patients with heart failure. J Am Heart Assoc 5:e002468PubMedPubMedCentral
35.
Zurück zum Zitat Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K (2016) Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 68:2497–2504PubMedPubMedCentral Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K (2016) Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 68:2497–2504PubMedPubMedCentral
36.
Zurück zum Zitat Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR, Investigators S (2017) Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med 376:641–651PubMedPubMedCentral Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR, Investigators S (2017) Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med 376:641–651PubMedPubMedCentral
37.
Zurück zum Zitat Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, Lopez-Jimenez F (2014) The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc 89:1368–1377PubMedPubMedCentral Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, Lopez-Jimenez F (2014) The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc 89:1368–1377PubMedPubMedCentral
38.
Zurück zum Zitat Shimada YJ, Tsugawa Y, Brown DF, Hasegawa K (2016) Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series. J Am Coll Cardiol 67:895–903PubMed Shimada YJ, Tsugawa Y, Brown DF, Hasegawa K (2016) Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series. J Am Coll Cardiol 67:895–903PubMed
39.
Zurück zum Zitat Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177PubMed Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, Group ESCSD (2018) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177PubMed
40.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH van der, Meer P, Group ESCSD (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH van der, Meer P, Group ESCSD (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200
41.
Zurück zum Zitat Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349:1050–1053PubMed Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349:1050–1053PubMed
42.
Zurück zum Zitat Banack HR, Kaufman JS (2014) The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med 62:96–102PubMed Banack HR, Kaufman JS (2014) The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. Prev Med 62:96–102PubMed
43.
Zurück zum Zitat Pi-Sunyer XF, Becker DM, Bouchard C, Carleton R, Colditz GA, Dietz WH, Foreyt JP, Garrison RJ, Grundy SM, Hansen BC, Higgins M, Hill JO, Howard BV, Kuczmarski RJ, Kumanyika S, Legako DR, Prewitt ET, Rocchini AP, Smith PL, Snetselaar LG, Sowers JR, Weintraub M, Williamson DF, Wilson TG (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 68(4):899–917 Pi-Sunyer XF, Becker DM, Bouchard C, Carleton R, Colditz GA, Dietz WH, Foreyt JP, Garrison RJ, Grundy SM, Hansen BC, Higgins M, Hill JO, Howard BV, Kuczmarski RJ, Kumanyika S, Legako DR, Prewitt ET, Rocchini AP, Smith PL, Snetselaar LG, Sowers JR, Weintraub M, Williamson DF, Wilson TG (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 68(4):899–917
44.
Zurück zum Zitat Coutinho T, Goel K, Correa de Sa D, Carter RE, Hodge DO, Kragelund C, Kanaya AM, Zeller M, Park JS, Kober L, Torp-Pedersen C, Cottin Y, Lorgis L, Lee SH, Kim YJ, Thomas R, Roger VL, Somers VK, Lopez-Jimenez F (2013) Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity”. J Am Coll Cardiol 61:553–560PubMed Coutinho T, Goel K, Correa de Sa D, Carter RE, Hodge DO, Kragelund C, Kanaya AM, Zeller M, Park JS, Kober L, Torp-Pedersen C, Cottin Y, Lorgis L, Lee SH, Kim YJ, Thomas R, Roger VL, Somers VK, Lopez-Jimenez F (2013) Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity”. J Am Coll Cardiol 61:553–560PubMed
45.
Zurück zum Zitat Sze S, Zhang J, Pellicori P, Morgan D, Hoye A, Clark AL (2017) Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. Clin Res Cardiol 106:533–541PubMed Sze S, Zhang J, Pellicori P, Morgan D, Hoye A, Clark AL (2017) Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. Clin Res Cardiol 106:533–541PubMed
Metadaten
Titel
Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative
verfasst von
Susan Stienen
João Pedro Ferreira
Nicolas Girerd
Kévin Duarte
Zohra Lamiral
John J. V. McMurray
Bertram Pitt
Kenneth Dickstein
Faiez Zannad
Patrick Rossignol
For the High-Risk Myocardial Infarction Database Initiative
Publikationsdatum
05.04.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 11/2019
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-019-01453-7

Weitere Artikel der Ausgabe 11/2019

Clinical Research in Cardiology 11/2019 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.